Bristol Myers Squibb (BMS) announced it will present data from research spanning 15 different cancers with high unmet need at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will take place from September 19 to 21, 2020.

The BMS presentations at ESMO will highlight clinical data evaluating various novel tumor targets in early-stage pipeline therapies and novel combinations in cancers, including non-Hodgkin lymphoma, extensive-stage small cell lung cancer, diffuse large B-cell lymphoma, and glioblastoma.

In research investigating renal cell carcinoma (RCC) treatments, the company will present data on nivolumab (Opdivo) use in combination with cabozantinib (Cabometyx, Exelixis) versus sunitinib in previously untreated advanced RCC. Additionally, results will be presented from a 4-year follow-up of a phase 3 study evaluating nivolumab plus ipilimumab (Yervoy) compared with sunitinib in patients with previously untreated advanced or metastatic RCC. This follow-up is the longest from a phase 3 trial of an immunotherapy-based combination in previously untreated advanced RCC.

The company will also present first disclosures of data from several phase 3 trials investigating treatments of gastrointestinal cancers, lung cancer, and melanoma.

“New data we are presenting at ESMO will highlight the potential to change the standard of care for certain cancers, demonstrate the value our therapies can bring to patients, and showcase how we are defining the future of medicine. We are also grateful for the tireless support from and collaboration with the cancer community, especially from investigators and patients, without whom our research would not be possible,” said Samit Hirawat, MD, executive vice president, chief medical officer, global drug development, BMS, in a press release.

Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need. Princeton, NJ: Bristol Myers Squibb; September 8, 2020. Accessed September 11, 2020.